Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
60 participants
INTERVENTIONAL
2009-05-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise
Endurance exercise
The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
Control group
Counseling
Counseling about exercise and behavioural techniques to reduce fatigue
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endurance exercise
The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
Counseling
Counseling about exercise and behavioural techniques to reduce fatigue
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hematological neoplastic disease
* Treatment with high-dose chemotherapy with peripheral blood stem cell transplantation in the previous 3 years
* Karnofsky-Index \> 80%
* Ability to understand German
Exclusion Criteria
* Psychosis
* Organic brain damage
* Dementia
* PBSCT in the previous 6 weeks
* Pathological stress test at admission
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Charite Universitätsmedizin Berlin
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fernando Dimeo, MD
Role: PRINCIPAL_INVESTIGATOR
Charite University, Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Charité Universitätsmedizin Berlin
Berlin, State of Berlin, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Fernando Dimeo, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EA4/028/09
Identifier Type: -
Identifier Source: org_study_id